Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside releases nitric oxide when it enters the bloodstream. The nitric oxide activates guanylate cyclase in vascular smooth muscle, increasing cyclic GMP levels, which cause smooth‑muscle relaxation and prompt dilation of both arteries and veins, leading to a swift fall in systemic vascular resistance.

The dosing regimen for Nipruss is individualized. A qualified prescriber determines the infusion rate and duration based on the patient’s clinical condition, blood pressure targets, and response to therapy, following established hospital protocols and monitoring guidelines.

Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should only be used when the potential maternal benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Nipruss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with agents such as nitroglycerin or hydralazine, sodium nitroprusside offers a more rapid and titratable onset of action, affecting both arterial and venous vessels. This allows precise blood pressure control, but it also carries a higher risk of cyanide accumulation, requiring careful monitoring.

Nipruss should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze or shake the vial before use.

Nipruss is supplied as an intravenous solution and must be administered by slow infusion through a calibrated IV pump or infusion set. Continuous blood pressure monitoring is essential, and the infusion rate is adjusted by the clinician to achieve the desired hemodynamic effect.

The most serious risks include cyanide toxicity, which can develop with prolonged high‑dose infusions, and severe hypotension leading to organ hypoperfusion. Methemoglobinemia and life‑threatening arrhythmias are also rare but critical complications that require immediate attention.

Patients with known hypersensitivity to sodium nitroprusside, those with severe anemia, or individuals with uncontrolled cyanide metabolism disorders should avoid Nipruss. Additionally, it is contraindicated in patients where rapid blood pressure reduction could compromise perfusion to vital organs.